Dr. Peter Coveney

Dr. Peter Coveney, a computational chemistry expert from University College London, discusses the challenges AI faces in drug discovery. Despite its promised speed and cost-efficiency, most AI-designed drugs have yet to reach approval. He reflects on the high-profile failures like Benevolent AI, and emphasizes that while generative AI may create novel molecules, many crucial development stages remain. Advocating for in silico trials and digital twins, he calls for realistic expectations about AI’s role in medicine and the need for addressing data biases.